



PRESS RELEASE:

For Immediate Release:

LATITUDE Announces Chinese Patent Granted to Nano-K™

SAN DIEGO – January 11, 2016 - **LATITUDE Pharmaceuticals, Inc. (LPI)**, a San Diego-based drug formulation developer, announced today that the State Intellectual Property Office or SIPO in China issued on January 7, 2016 a Notification of Undergoing Registration Procedures and a Notification of Granting Patent Right for Nano-K™, a Nanoemulsion Composition containing Vitamin K.

Nano-K™ is an injectable Vitamin K product that uses LATITUDE's proprietary parenteral nanoemulsion formulation platform (Nano-E™). Nano-K™ is designed to replace the current vitamin K products (e.g., AquaMEPHYTON) which contain the toxic solubilizer Cremophor and are injected into every newborn in the US (4.3 million/yr) as a prophylactic therapy for vitamin K deficiency bleeding.

Nano-K™ is bioequivalent to AquaMEPHYTON in animal studies and may qualify for an accelerated regulatory approval under a 505(b)(2) NDA. And, since Cremophor is associated with hypersensitivity reactions, a product like Nano-K™ that is free of toxic solubilizers like Cremophor would be especially attractive for the treatment of newborns.

About LATITUDE Pharmaceuticals, Inc.

LPI is a drug delivery company that develops new intellectual property for the biotech and pharmaceutical industries through IP-driven, leading-edge drug formulation approaches and technologies. **LPI** has built a solid reputation as an innovator and for its successful track record in formulating difficult and/or highly insoluble drug molecules.

For more information, please visit the company's website at www.latitudepharma.com or send inquiry to info@latitudepharma.com.